论文部分内容阅读
目的探讨依达拉奉对糖尿病大鼠视网膜氧化应激的影响及意义。方法选择2014年6—9月30只雄性SD大鼠作为研究对象,适应环境后,将研究对象随机分为正常对照组、糖尿病组和依达拉奉干预组各10只。用细胞裂解液提取各组大鼠视网膜的总蛋白,分别用超氧化物歧化酶(superoxide dismutase,SOD)活性试剂盒、谷胱甘肽(glutathione,GSH)活性试剂盒、丙二醛(malondialdehyde,MDA)含量试剂盒检测视网膜中SOD活性、GSH活性以及MDA含量。应用Western-blot技术检测标本中神经胶质纤维酸性蛋白(glial fibrillary acidic protein,GFAP)的表达差异,以β-actin蛋白的表达作为内参对照。计量资料采用单因素方差分析,P<0.05为差异有统计学意义。结果正常对照组、糖尿病组、依达拉奉干预组的SOD含量分别为(300.11±4.52)、(105.49±5.82)、(254.38±10.09)U/mg,GSH含量分别为(48.56±2.17)、(15.26±3.52)、(30.24±1.91)mg/g,MDA含量分别为(6.56±0.43)、(19.05±1.43)、(9.56±1.25)mmol/mg,3组SOD活性、GSH活性、MDA值比较,差异均有统计学意义(均P<0.05)。Western条带结果显示正常对照组大鼠视网膜中GFAP表达量较低,而糖尿病模型大鼠的GFAP表达量较正常对照组明显升高,差异有统计学意义(P<0.05),通过依达拉奉干预的糖尿病大鼠视网膜中GFAP表达量较糖尿病模型组显著降低,差异有统计学意义(P<0.05)。结论依达拉奉可以抑制SOD活性、GSH活性的下降,减少MDA的生成,从而起到减轻氧化应激损伤、保护视网膜的作用,使得糖尿病大鼠视网膜中的GFAP表达量下调。依达拉奉的抗氧化保护作用提示依达拉奉可以作为早期糖尿病性视网膜病变(diabetic retinopathy,DR)干预的一个药物选择,但是其具体有效性还有待进一步研究。
Objective To investigate the effect of edaravone on retinal oxidative stress in diabetic rats and its significance. Methods Thirty male SD rats from June to September in 2014 were selected as study subjects. After adapting to the environment, the subjects were randomly divided into normal control group, diabetes group and edaravone intervention group, each with 10 rats. The total protein in the retina of each group was extracted by cell lysis solution. The superoxide dismutase (SOD) activity kit, glutathione (GSH) activity kit, malondialdehyde MDA) content kit detection of retinal SOD activity, GSH activity and MDA content. The expression of glial fibrillary acidic protein (GFAP) was detected by Western-blot. The expression of β-actin protein was used as an internal control. Measurement data using one-way analysis of variance, P <0.05 for the difference was statistically significant. Results The SOD levels in the normal control group, diabetic group and edaravone intervention group were (300.11 ± 4.52), (105.49 ± 5.82) and (254.38 ± 10.09) U / mg respectively, and the GSH contents were (48.56 ± 2.17) (15.26 ± 3.52) and (30.24 ± 1.91) mg / g respectively, the contents of MDA were (6.56 ± 0.43), (19.05 ± 1.43) and (9.56 ± 1.25) mmol / Comparison, the differences were statistically significant (P <0.05). The results of Western blotting showed that the expression of GFAP in retina of normal control group was lower than that of normal control group, while the expression of GFAP in diabetic model group was significantly higher than that of normal control group (P <0.05) Compared with diabetic model group, the GFAP expression in retina of retina intervention group was significantly lower (P <0.05). Conclusion Edaravone can inhibit the activity of SOD, decrease the activity of GSH and decrease the production of MDA, which can reduce the damage of oxidative stress and protect the retina, and decrease the expression of GFAP in the retina of diabetic rats. The anti-oxidative protection of edaravone suggests that edaravone can be used as a drug in the early stage of diabetic retinopathy (DR). However, the specific efficacy of edaravone remains to be further studied.